FindTrial
Sign In

Comparison of spironolactone and trichlormethiazide as add-on therapy to renin-angiotensin blockade for reduction of albuminuria in diabetic patients

Comparison of spironolactone and trichlormethiazide as add-on therapy to renin-angiotensin blockade for reduction of albuminuria in diabetic patients - Spironolactone and thiazide in patients with diabetic nephropathy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000008914
Enrollment
40
Registered
2012-09-13
Start date
2001-10-12
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic patients with persistent albuminuria

Interventions

Oral administration of spironolactone (25 mg/day) Oral administration of trichlormethiazide (2 mg/day)

Sponsors

Diabetes Center, Tokyo Women's Medial University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Japanese type 2 diabetic patients with urinary albumin-to-creatinine ratio (ACR) from first morning urine ≥ 100 mg/g and use of an ACE inhibitor or ARB for at least 6 months.

Exclusion criteria

Exclusion criteria: Patients with clinically significant heart, liver, infectious, or malignant disease, those with serum creatinine was ≥ 2.0 mg/dL, or those with serum potassium was ≥ 5.0 mEq/L or < 3.5 mEq/L.

Design outcomes

Primary

MeasureTime frame
Change in albuminuria at 24 weeks of treatment—

Countries

Japan

Contacts

Public ContactTetsuya Babazono

Tokyo Women's Medial University School of Medicine Diabetes Center

03-3353-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026